L’eccessiva e prolungata esposizione solare non comporta solo il rischio del precoce invecchiamento della pelle e delle complicazioni oncologiche, causate dai raggi ultravioletti (UV) (1-4).
Secondo alcune recenti ricerche i raggi UV possono innescare danni anche al sistema nervoso centrale e minacciare la cognitività (1-4).
Per questo gli studi clinici sottolineano l’importanza di proteggere e recuperare l’integrità della pelle per tutelare la salute dell’intero organismo, attraverso l’uso appropriato dei fattori di protezione solare, ed altre sostanze bioattive per via topica ed orale (1-6).
Sono questi i principali messaggi emersi da un articolo pubblicato a maggio 2026 dalla rivista medica Photodermatology, Photoimmunology & Photomedicine (1), ed ulteriormente confermati da altre indagini mediche (2-6).
RAGGI UV: EFFETTI CUTANEI ED EXTRA-CUTANEI
Le conseguenze neurologiche dovute all’eccessiva ed incontrollata esposizione solare, derivano dalle alterazioni delle complesse e reciproche relazioni tra la pelle ed altri organi e sistemi, mediate dai microrganismi presenti nell’intestino e sulla cute, il cosiddetto microbiota (1-6).
Ne sono un’esempio i collegamenti: pelle - cervello; cervello - intestino; pelle - cervello - intestino ecc. (1-6).
Quando queste connessioni inter-organo si alterano, il nostro organismo subisce un’accelerazione dell’invecchiamento biologico, con il conseguente aumento del rischio di malattie croniche, ad iniziare dal declino cognitivo e la malattia di Alzheimer (1-19).
In pratica si instaurano dei circoli viziosi tra i vari organi, intestino e pelle, che provocano il precoce invecchiamento cutaneo, insorgenza di malattie infiammatorie cutanee, depressione, ansia, complicazioni cardiovascolari e metaboliche (20-34).
FATTORI E CONDIZIONI AGGRAVANTI
Oltre all’eccessiva esposizione ai raggi UV questi processi fisiopatologici vengono aggravati da molteplici fattori, es.: inquinanti ambientali, alcol, fumo, sedentarietà ecc. (17, 18, 19).
Anche particolari condizioni come la menopausa e la parodontite, caratterizzare da cambiamenti del microbiota intestinale, vaginale ed orale, possono deteriorare i legami inter-organo con le relative complicazioni per la salute (38-66).
STRATEGIE DI PREVENZIONE
Molti meccanismi fisiopatologici sopra descritti possono essere contrastati in modo significativo da:
• alimentazione di stile mediterraneo e sane abitudini di vita (67, 68);
• strategie nutraceutiche, dermocosmeceutiche, incluso l’uso sistematico dei fattori di protezione solare (1, 52-62).
L’adeguato apporto alimentare e/o nutraceutico di vitamine del gruppo B (es.: B2, B6, B12), dotate di attività vitali per l’organismo umano, permette di regolare la composizione del microbiota intestinale e svolgere significative attività neuroprotettive (24, 69, 70).
I polifenoli (es.: curcumina, resveratrolo) sono potenti antiossidanti, influenzano in modo positivo il microbiota intestinale e rallentano i processi dell’invecchiamento (24, 71-74).
Nel peri- e post menopausa risulta di particolare importanza il supporto del resveratrolo, un polifenolo che simula l’attività degli estrogeni, e dimostra benefici per il metabolismo osseo, la prevenzione cardiometabolica e neurocognitiva (69, 75-82).
Inoltre, per proteggere la salute cutanea, neurocognitiva e cardiometabolica gli studi clinici hanno individuato anche i benefici di altri micronutrienti e principi naturali:
acidi grassi polinsaturi, probiotici, polifenoli, vitamine, coenzima Q10, magnesio, zinco, fibre alimentari (67, 68, 69, 78-89, 91).
MESSAGGI CHIAVE
• Le più recenti ricerche sottolineano l’importanza di conservare e recuperare la salute della pelle per prevenire vari disturbi clinici, causati dalle alterazioni dei complessi legami tra pelle ed altri organi, come il cervello.
• I nutraceuitici ed i dermocosmeceutici, con fattori di protezione solare, creati dalla ricerca Mitochon srl https://www.mitochon.it/ (Nota 1) dimostrano significativi risultati clinici contro l’invecchiamento cutaneo e sistemico (5, 6, 7, 38, 55, 56, 78-85, 90, 91).
•
• Secondo le più moderne esperienze cliniche, l’associazione dei trattamenti topici e per via orale deve essere iniziata intorno ai 30 anni d’età, quando si manifestano i primi segni dell’invecchiamento cutaneo, ed altri importanti cambiamenti biologici dell’organismo umano.
• Almeno un mese di trattamenti continuativi risulta necessario per ottenere i migliori risultati, come dimostrato dagli studi clinici svolti da Mitochon srl https://www.mitochon.it/.
Nota 1
Prodotti della ricerca Mitochon srl https://www.mitochon.it/ :
• La linea dermocosmeceutica bit.ly/4aY7Pyy è stata concepita per proteggere e rigenerare le attività delle cellule cutanee e ridurre i segni dell’invecchiamento, attraverso l’azione sinergica di: coenzima Q10, acido folico, precursori della vitamina C, N-acetilglucosamina (NAG) precursore di acido ialuronico, glutatione, tocoferolo, retinil palmitato, ceramidi, acidi grassi ecc..
• Ulteriore elemento distintivo dei dermocosmeceutici di Mitochon srl la presenza di fattori di protezione solare: SPF 30 nell’emulsione giorno e SPF 6 nel siero concentrato.
• Gli integratori Mitofast® bit.ly/3VUlGkS e Mitofast B12 bit.ly/4d5ll4P, contribuiscono ad attenuare i fenomeni biomolecolari dell’invecchiamento cutaneo e sistemico, intervenendo sui principali hallmarks of aging, es.: disfunzione mitocondriale, infiammazione sistemica, alterazioni epigenetiche / metilazione del DNA, senescenza cellulare, disbiosi.
• Mitofast® è una formulazione orosolubile, studiata con una precisa stechiometria di: resveratrolo, coenzima Q10, acido folico, vitamina C, N-acetilcisteina (NAC) precursore di glutatione, N-acetilglucosamina (NAG) per promuovere la sintesi di acido ialuronico.
• Mitofast B12 è un integratore liquido formulato per somministrare in modo mirato la ciancobalamina, la forma di vitamina B12 farmacologicamente più adatta per l’uso orale.
Bibliografia
1. Deriouich M, Dompmartin A, L'Orphelin JM. Ultraviolet Radiations Impact on the Skin-Brain Axis: A Literature Review of our Current Knowledge. Photodermatol Photoimmunol Photomed. 2026 May;42(3):e70097. doi: 10.1111/phpp.70097.
2. Yu X, Zhu H, Su Y, Zhou L, Chen Z, Li P, Wang Y. Brain-organ axis: How does stress regulate peripheral immunity through neural signaling? Phys Life Rev. 2026 Jul;57:164-179. doi: 10.1016/j.plrev.2026.04.001.
3. Liao J, Mou H, Luo S, Shen L, Jiao B. Microbiota and Alzheimer's disease: mechanistic insights from a multi-organ perspective. Transl Neurodegener. 2026 Feb 11;15(1):3. doi: 10.1186/s40035-026-00541-9.
4. Tan CC, Soh KV, Wang E, Choi EC. The brain-skin connection: A narrative review of neuroendocrine and immune pathways. JAAD Int. 2025 Oct 28;24:112-123. doi: 10.1016/j.jdin.2025.10.008.
5. Mini-Review Over 50 salute cutanea e benessere psicofisico 2025 https://www.mitochon.it/la-salute-cutanea-negli-over-50-per-il-benessere-psicofisico/?v=0d149b90e739
6. Mini-Review Salute della pelle neuroprotezione / Vitamina B12-acido folico 2025 https://www.mitochon.it/notizie-flash-2025/?v=0d149b90e739
7. Mini-Review Peakspan: una nuova dimensione dell’invecchiamento 2026 https://www.mitochon.it/peakspan-una-nuova-dimensionedellinvecchiamento/?v=0d149b90e739
8. Uranga RM, Allani SK. From Lipids to Mitochondria: Shared Metabolic Alterations in Obesity and Alzheimer’s Disease. Cells. 2026; 15(8):672. https://doi.org/10.3390/cells15080672
9. Wang S, Liu M, Shi X, Xiong T, Li R, Zheng W, Huang Q, Nan Y, Ai K. Targeting mitochondrial dysfunction to quell neuroinflammation in central nervous system (CNS): a new strategy for treating CNS disease with nanomedicines. Sci Bull (Beijing). 2026 May 19:S2095-9273(26)00519-0. doi: 10.1016/j.scib.2026.05.020.
10. Dieter F, Jacobs K, Quentin A, Prvulovic D, Reif A, Pantel J, Pilatus U, Hattingen E, Matura S, Eckert GP. Mitochondrial dysfunction in peripheral mononuclear blood cells (PBMC) of individuals with mild cognitive impairment. Geroscience. 2026 Apr;48(2):2887-2901. doi: 10.1007/s11357-025-01813-4.
11. Pinky, Wali Z, Neha, Tiwari P, El-Tanani M, Rabbani SA, Parvez S. Aging and Alzheimer's: the critical role of mitochondrial dysfunction and synaptic alterations. Front Synaptic Neurosci. 2026 Jan 2;17:1676317. doi: 10.3389/fnsyn.2025.1676317.
12. Xiao X, Yan X, Liang C, Yang Y. Metabolic dysfunction and mitochondrial failure in Alzheimer's disease: integrating pathophysiology, clinical evidence and emerging interventions. Front Neurol. 2026 Feb 26;17:1772036. doi: 10.3389/fneur.2026.1772036.
13. Shimoda N. From research to clinical practice: DNA methylation signatures as diagnostic tools for Alzheimer's disease. Epigenomics. 2026 Mar;18(3):303-310. doi: 10.1080/17501911.2026.2635932.
14. Kumar V, Shukla R, Gangani S, Joseph R, Jain S, Yadav H. Epigenetics and the gut-brain axis: Insights into DNA methylation, aging, and Alzheimer disease. J Pharmacol Exp Ther. 2026 Apr;393(4):104299. doi: 10.1016/j.jpet.2026.104299.
15. Katsigianni S, Koutsouraki E. Gut Microbiota Dysbiosis and Neuroinflammation in Alzheimer's Disease: a Systematic Review of Mechanistic Insights. Mol Neurobiol. 2026 May 12;63(1):623. doi: 10.1007/s12035-026-05914-9.
16. Nayak RK, Mohapatra SR, Sahoo SK, Sahu SK, Chowdhury B, Banu Z, Das NR. Gut Microbiota Dysbiosis in Alzheimer's Disease and Possible Therapeutic Options. Curr Alzheimer Res. 2026 May 4. doi: 10.2174/0115672050448298260303052535.
17. Yin Q, Schöttker B, Holleczek B, Fan Z, Stevenson-Hoare J, Brenner H. Tracking DNA methylation-based biological age over 8 years and its association with mortality in community-dwelling older adults. Clin Epigenetics. 2026 Apr 16;18(1):65. doi: 10.1186/s13148-026-02067-3.
18. Huang R, Bo Y, Guo J, Liu Y, Li C, Han J, Lu S, Suo X. Accelerated biological aging and brain structural alterations linking air pollution to dementia risk: a prospective cohort study. J Nutr Health Aging. 2026 May;30(5):100836. doi: 10.1016/j.jnha.2026.100836.
19. Liu Z, Ziogas A, Zhang Y, Gupta MK, Föhse K, Taks E, Dulfer E, Sarlea A, Ventriglia L, Geckin B, Ballan M, van Unen N, Helder L, Trittel S, Riese P, Moorlag S, de Bree C, Koeken V, Mourits V, Jaeger M, Pessler F, Guzmán CA, Joosten LAB, Li Y, Xu CJ, Netea MG. Interferon-related inflammaging links epigenetic age acceleration to multimorbidity. Cell Genom. 2026 Apr 17:101218. doi: 10.1016/j.xgen.2026.101218.
20. Mishra AK, Verma S, Mishra A, Khan G, Singh H. Unlocking the role of microbiome through gut-skin axis to alleviate aging: current perspectives and future scope. Geroscience. 2026 Mar 21. doi: 10.1007/s11357-026-02211-0.
21. Yiğit İK, Türsen Ü, Türsen B, Solak B, Bakay ÖSK, Kroumpouzos G. Probiotics for skin aging and skin conditions in the elderly. Clin Dermatol. 2026 Feb 24:S0738-081X(26)00057-X. doi: 10.1016/j.clindermatol.2026.02.016.
22. Kopalli SR, Wankhede N, Rahangdale SR, Sammeta S, Aglawe M, Koppula S, Taksande B, Upaganlawar A, Umekar M, Kale M. Age-driven dysbiosis: gut microbiota in the pathogenesis and treatment of aging disorders. Biogerontology. 2026 Jan 23;27(1):42. doi: 10.1007/s10522-026-10389-1.
23. Fan T, Peng J, Liang H, Chen W, Wang J, Xu R. Potential common pathogenesis of several neurodegenerative diseases. Neural Regen Res. 2026 Mar 1;21(3):972-988. doi: 10.4103/NRR.NRR-D-24-01054.
24. Chen N, Chan CK, Khan FU, Makhijani P, Valentino TR, Winer S, Luk CT, Winer DA. Gut microbiota-derived metabolites as immune modulators in aging and age-related chronic inflammatory diseases. Ageing Res Rev. 2026 Apr;116:103036. doi: 10.1016/j.arr.2026.103036.
25. Kim JY. Gut Microbiota, Probiotics, and Aging: Molecular Mechanisms and Implications for Healthy Aging. J Microbiol Biotechnol. 2026 Jan 18;36:e2511046. doi: 10.4014/jmb.2511.11046.
26. Xie M, Kong L, Hou L, Chen Y, Hou J. Atopic dermatitis: Multi-omics insights into microbiota-driven modulation of the gut-skin axis. Microb Pathog. 2026 Jul;216:108504. doi: 10.1016/j.micpath.2026.108504.
27. Andrzejczak K, Kucharczyk E, Sternak A, Busłowicz T, Ponikowska M. Gut Dysbiosis and the Molecular Landscape of the Gut-Skin Axis: Comparative Insights and Therapeutic Implications for Atopic Dermatitis and Psoriasis. Cells. 2026 Mar 26;15(7):594. doi: 10.3390/cells15070594.
28. Zhang R, Shi J, Xu Y, Yao S, Raghavan V, Wang J. The role of the oral microbiota in allergic diseases: Current understandings and future trends. Microbiol Res. 2025 Oct;299:128254. doi: 10.1016/j.micres.2025.128254.
29. Guo Z, Yang J, Zang R, Yang Y, Wang Q, Xu C. The brain-gut-skin axis in inflammatory and disfiguring skin diseases: mechanistic insights, clinical correlations, and therapeutic strategies. Front Immunol. 2026 Feb 27;17:1737303. doi: 10.3389/fimmu.2026.1737303.
30. Lazić Mosler E, Vekić Mužević M, Karlović D, Tarle M, Raguž M. Revisiting Rosacea Through the Skin-Gut-Brain Axis: A Neuroimmune Perspective. Life (Basel). 2026 Feb 18;16(2):347. doi: 10.3390/life16020347.
31. Ramirez-Posada M, Guillen-Burgos HF. Skin-Brain Axis: Biological Foundations and Clinical Implications. J Acad Consult Liaison Psychiatry. 2026 Apr 22:S2667-2960(26)00049-2. doi: 10.1016/j.jaclp.2026.04.006.
32. Coccurello R. The skin microbiome and affective symptoms: neuroimmune, neuroendocrine, and sensory pathways linking inflammatory dermatoses to mood and anxiety burden. Front Neuroendocrinol. 2026 Apr 22;81:101251. doi: 10.1016/j.yfrne.2026.101251.
33. Ponikowska M, Hill L, Lee CS, Barisone M, Ponikowski P, Aldossary HM, Jędrzejczyk M, Kubielas G, Uchmanowicz I. Cardiovascular Disease and Psoriasis. Dermatol Ther (Heidelb). 2026 Jan;16(1):155-169. doi: 10.1007/s13555-025-01566-0.
34. Karmbir, Faisal SM, Narang RK, Kurmi BD, Kaur K, Sharma A. Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities. Inflammopharmacology. 2026 Mar;34(3):1317-1330. doi: 10.1007/s10787-025-02027-y.
35. Narang T, Singh LK, Kumaran MS, Parsad D, Mehra A. Cognitive Impairment among Patients with Chronic Skin Inflammatory Disorder: A Hidden Link. Indian Dermatol Online J. 2026 May 1;17(3):367-373. doi: 10.4103/idoj.idoj_137_25.
36. Cai Y, Dai W, Liu F, Li Z, Liu G. Causal Associations Between Chronic Inflammatory Skin Diseases and Alzheimer's Disease: A Bidirectional Two-Sample Mendelian Randomization Study. Clin Cosmet Investig Dermatol. 2026 Mar 17;19:589176. doi: 10.2147/CCID.S589176.
37. Qu T, Zhao Q, Fang J, Liang Z. Bidirectional mediation between microbiota and immune system in Parkinson disease: A two-sample Mendelian randomization study. Medicine (Baltimore). 2026 May 8;105(19):e48681. doi: 10.1097/MD.0000000000048681.
38. Mini-Review Salute orale - Invecchiamento 2025 https://www.mitochon.it/la-salute-orale-contro-linvecchiamento-e-le-malattie-correlate/?v=0d149b90e739
39. Li F, Liang X, Li J, Cui M, Ho TE, Li J, Yuan Z, Meng W, Man Lo EC, Fan M, Zhang Z, Jin L, Chen X, Lu H, Jiang Y. Oral microbiome perturbations link periodontal health to cognitive ageing in a large community cohort. EBioMedicine. 2026 Apr;126:106231. doi: 10.1016/j.ebiom.2026.106231.
40. Ashford M, Ziaei H, Rezaei N. Impact of Oral Immunity on Neuroinflammation and Neurodegenerative Diseases. Adv Exp Med Biol. 2026;1492:255-272. doi: 10.1007/978-3-032-03176-1_13.
41. Miranda V, Laarej K, Cavaliere C. The Oral Microbiota: Implications in Mucosal Health and Systemic Disease-Crosstalk with Gut and Brain. Cells. 2026 Jan 4;15(1):82. doi: 10.3390/cells15010082.
42. Zavala-Medina LC, Salas-Leiva JS, Villegas-Mercado CE, Arreguín-Cano JA, Soto-Barreras U, Santana-Delgado SA, Larrinua-Pacheco AD, García-Vega MF, Bermúdez M. Oral Dysbiosis and Neuroinflammation: Implications for Alzheimer's, Parkinson's and Mood Disorders. Microorganisms. 2026 Jan 8;14(1):143. doi: 10.3390/microorganisms14010143.
43. Ebihara S, Kamada N. The Oral-Gut Axis: Bidirectional Interactions Between Microbiome and Diseases. J Periodontal Res. 2026 May 5. doi: 10.1111/jre.70116. Epub ahead of print. PMID: 42084201.
44. Fusco W, Adolph T, Cammarota G, Gasbarrini A, Ianiro G, Tilg H. Gut microbiota and atherosclerosis. Gut. 2026 Apr 7;75(5):1067-1077. doi: 10.1136/gutjnl-2025-335610.
45. Thouvenot K, Serrat F, Lenclume V, Doussiet E, Belda E, Taïlé J, Alili R, Rondeau P, Clément K, Meilhac O, Le Moullec N, Gonthier MP. Periodontitis in Patients With Severe Obesity: From the Oral and Gut Microbiota Dysregulation to the Visceral Adipose Tissue Inflammatory and Metabolic Disorders. FASEB J. 2026 May 15;40(9):e71828. doi: 10.1096/fj.202600054R.
46. Matwiejuk, M.; Myśliwiec, H.; Mikłosz, A.; Chabowski, A.; Flisiak, I. Common Skin Diseases and Metabolic Syndrome: A Proinflammatory Chemokine Perspective. Metabolites 2026, 16, 253. https://doi.org/10.3390/metabo16040253
47. Woo YR, Kim HS. Obesity, skin disorders, and the microbiota: Unraveling a complex web. J Microbiol. 2026 Jan;64(1):e2508007. doi: 10.71150/jm.2508007.
48. Zhao W, Zhou X, Cai H, Tang T, Shen Y, Sun Z, Zhu J, Yu Y. The relation between gut microbiota, brain structure and cognitive function in metabolic syndrome. Brain Behav Immun. 2026 Feb;132:106209. doi: 10.1016/j.bbi.2025.106209.
49. Zhao Y, Zhang C, Chang X, Zhang J, Shu C, Lin C, Hou J. Causal association between periodontitis and systemic diseases: a systematic review and meta-analysis of mendelian randomization studies. BMC Oral Health. 2026 Jan 30;26(1):383. doi: 10.1186/s12903-026-07725-9.
50. Zhang Y, Wei T, Zhao C, Zhang L. The Role of the Vaginal Microbiome in Gynecological Diseases: Mechanistic Insights and Emerging Interventions. Biology (Basel). 2026 Mar 5;15(5):432. doi: 10.3390/biology15050432.
51. Chaudhary R, Bansal N, Sharma S, Gupta S, Chopra K, Bansal S. Bidirectional Communication of Estrogen in Gut-Brain Axis: Evidence from Preclinical and Clinical Studies. Curr Drug Targets. 2026 Jan 15. doi: 10.2174/0113894501406082251019170714.
52. Ferrando ML, Busonero F, Crobu F, Sanna S. Aging in women - The microbiome perspective. Ageing Res Rev. 2026 Jan;113:102950. doi: 10.1016/j.arr.2025.102950.
53. Castaneda R, Uddenberg ER, Hurtado Andrade MD, Meek JL, Frankhouser KN, Faubion SS, Chini EN, LeBrasseur NK, Brar PK, Shufelt CL. Biological markers of aging across the menopause transition: current evidence. Menopause. 2026 May 5. doi: 10.1097/GME.0000000000002802
54. Tahtouh Zaatar M, Othman R, Abushawish M, Akl M, Alachkar MT, Almatboona G, Alriyami F, Alshaibani A, Ashkanani D, Basharova M, Imam M, Khassay N, Mikhael MS, Naderi Far R, Shaqra S, Verwey K, Suleimanova A, Yousafzada M, Burmagina Y. The Women's Microbiome: Molecular Insights, Clinical Gaps, and Future Frontiers in Precision Health with Implications for Gulf Cooperation Council Populations. Int J Mol Sci. 2026 Mar 10;27(6):2521. doi: 10.3390/ijms27062521.
55. Mini-Review Menopausa antiaging cutaneo 2025 https://www.mitochon.it/6518/?v=0d149b90e739
56. Mini-Review Pelle - Infiammazione cronica 2025 https://www.mitochon.it/la-pelle-come-scudo-contro-linfiammazione-cronica-dellorganismo/?v=0d149b90e739
57. Roster K, Fleshner L, Karatas TB, Ecanow A, Sayegh A, Farabi B, Marmon S. Menopause and Common Dermatoses: A Systematic Review. Am J Clin Dermatol. 2026 Jan;27(1):67-84. doi: 10.1007/s40257-025-00994-0.
58. Lephart ED, Draelos ZD. Overview of Aging, Skin Health, Estrogen, Menopause and HRT. Life (Basel). 2026 Mar 2;16(3):401. doi: 10.3390/life16030401.
59. Valerieva E, Vasileva M, Baynova K, Krusheva B, Petkova E, Nenova M, Novakova P, Staevska M, Cimbollek S, Valerieva A. Women hormones and hypersensitivity: allergic diseases in menopause. Front Allergy. 2026 Apr 8;7:1777688. doi: 10.3389/falgy.2026.1777688.
60. Gröne D, Fida M, de Oliveira GV, Kroumpouzos G. Aesthetically relevant symptoms of menopause transition: Impact and approach to management. Clin Dermatol. 2026 Mar-Apr;44(2):348-355. doi: 10.1016/j.clindermatol.2026.01.009.
61. Marano G, d'Abate C, Ianes I, Sorrenti G, Traversi G, Esposito R, Pavese F, D'Angelo T, Fuso P, Franceschini G, Paris I, Mazza M. The Gut Microbiota in Perimenopausal Anxiety: A Novel Therapeutic Pathway Through Diet. Nutrients. 2026 Feb 26;18(5):743. doi: 10.3390/nu18050743.
62. Wang X, Lin Y, Zhou M. Pathogenesis and potential therapies for perimenopausal depression: Insights from the estrogen-gut microbiota axis. Front Neuroendocrinol. 2026 Jan;80:101233. doi: 10.1016/j.yfrne.2026.101233.
63. Stapleton HM, Borges DS, Trindade EBSM, Yuan Q. Sex-dependent locus coeruleus vulnerability in Alzheimer's disease: gut dysbiosis as a driver and probiotic intervention as rescue. Biol Sex Differ. 2026 Jan 27;17(1):34. doi: 10.1186/s13293-026-00834-8.
64. Jarrín-Orozco MP, García-Nicolás M, Romo-Vaquero M, Carrascosa C, Berná J, Puigcerver J, Saura-Sanmartín A, Ávila-Gálvez MÁ, Espín JC. Precision health targeting TMAO in postmenopausal women: polyphenol effects modulated by urolithin A and equol metabotypes in a randomised, placebo-controlled crossover trial. Food Funct. 2026 Feb 23;17(4):2037-2049. doi: 10.1039/d5fo05461c.
65. Reytor-González C, Verde L, Annunziata G, Román-Galeano NM, Horowitz R, Galasso M, Muscogiuri G, Frias-Toral E, Simancas-Racines D, Barrea L. The Role of Gut Microbiota in Postmenopausal Women: Implications for Lipid Metabolism and Targeted Nutritional Interventions. Curr Nutr Rep. 2026 Mar 28;15(1):32. doi: 10.1007/s13668-026-00752-6.
66. Zhao W, Zhou X, Cai H, Tang T, Shen Y, Sun Z, Zhu J, Yu Y. The relation between gut microbiota, brain structure and cognitive function in metabolic syndrome. Brain Behav Immun. 2026 Feb;132:106209. doi: 10.1016/j.bbi.2025.106209.
67. Çelik MN, Dazıroğlu MEÇ, Pınar BA, Nanì MF, Romano B, Ağagündüz D, Capasso R. Microbiome crosstalk and nutrition: the interplay between gut microbiota-organ axis and dietary factors. Food Res Int. 2026 May 31;232:118945. doi: 10.1016/j.foodres.2026.118945.
68. Rodríguez-Vera D, Gómez-Martínez MA, Herrera-Picazo MV, Robledo LA, Tufiño C, Bustamante-Tenorio CC, Soriano-Ursúa MA, Morales-González Á, Madrigal-Santillán EO, Vergara-Castañeda A, Morales-González JA. Nutrient-Sensitive Epigenetic Modifiers as Candidate Biomarkers of Metabolic Dysfunction in Obesity: A Nutrigenomic Review. Int J Mol Sci. 2026 May 14;27(10):4372. doi: 10.3390/ijms27104372.
69. Castillo-Moral Á, Toda-Ferran C, Bulló M, Teichenné J, Escoté X. Nutraceuticals and the Microbiota-Gut-Brain Axis: A Pathway for Preventing Cognitive Decline. Nutr Rev. 2026 Mar 24:nuag017. doi: 10.1093/nutrit/nuag017.
70. Baddam S, Khan KM, Jialal I. Folic Acid Deficiency. 2025 Jun 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
71. Toderescu CD, Parveen M, Trifunschi S, Oancea A, Jurj GCC, Cresneac IG, Munteanu MF, Ciopanoiu I, Boru C, Pogurschi EN, Ionite C, Stefanache A, Lungu II. Dietary Polyphenols as Modulators of Bifidobacterium in the Human Gut Microbiota. Nutrients. 2026 Feb 27;18(5):782. doi: 10.3390/nu18050782.
72. Tang P, Feng H, Zhang D, Wu J, Zhou Y, Feng W, Peng C. Dietary Polyphenols in Metabolic Diseases: Roles of Gut Microbiota-Derived Metabolites. Phytother Res. 2026 Mar;40(3):1408-1445. doi: 10.1002/ptr.70180.
73. Sbai O, Perrone L, Poucheret P. The Role of Polyphenols on Cognitive Function and Dementia Through Gut–Microbiota–Brain Axis Modulation: A Narrative Review. Nutrients. 2026; 18(11):1697. https://doi.org/10.3390/nu18111697
74. Sánchez-Martínez L, Tosi N, Bragazzi NL, Bresciani L, Del Rio D, Periago MJ, Mena P, González-Barrio R. Metabolomic profiling of urinary phenolic compounds in postmenopausal women after consumption of dark chocolate, green tea, and fruit juice. Food Funct. 2026 Apr 27;17(8):3484-3498. doi: 10.1039/d5fo04088d.
75. Hecht S, Wittstein J, Kimura Y, Arias C. Critical implications of female bone metabolism in orthopedics: state of the art. J ISAKOS. 2026 May 7:101133. doi: 10.1016/j.jisako.2026.101133.
76. Sánchez-Martínez L, González-Barrio R, Periago MJ. The Potential Role of Dietary (Poly)phenols in Cardiometabolic Risk During Menopause: A Narrative Review. Nutrients. 2026 Mar 31;18(7):1130. doi: 10.3390/nu18071130.
77. Shanaida M, Oleshchuk O, Gontova T, Fira L, Beley N, Herasymets I, Mocherniuk K, Lukanyuk M, Koshovyi O, Raal A, Lykhatskyi P, Fira D, Beley S, Bjørklund G. The Anti-Aging Benefits of Phytoestrogens: Insights and Evidence. Curr Med Chem. 2026 Feb 19. doi: 10.2174/0109298673388265251016052311.
78. Mini-Review Antiaging cognitivo 2025 https://www.mitochon.it/antiaging-cognitivo/?v=0d149b90e739
79. Mini-Review Antiaging cardiovascolare 2025 https://www.mitochon.it/antiaging-cardiovascolare/?v=0d149b90e739
80. Mini-Review Antiaging muscolare 2025 https://www.mitochon.it/antiaging-muscolare/?v=0d149b90e739
81. Mini-Review Osteoporosi - Resveratrolo 2025 https://www.mitochon.it/osteoporosi-nel-post-menopausa-attualita-sul-ruolo-del-resveratrolo-altri-antiossidanti-e-vitamine/?v=0d149b90e739
82. Mini-Review Sovrappenso / Obesità - Resveratrolo - Antiossidanti 2025 https://www.mitochon.it/sovrappeso-obesita-quale-contributo-dal-resveratrolo-ed-altri-antiossidanti/?v=0d149b90e739
83. Mini-Review Coenzima Q10 - vitamine B - aging cutaneo 2026 https://www.mitochon.it/6-highlights-2026-su-coenzima-q10-vitamine-b-e-aging-cutaneo/?v=0d149b90e739
84. Mini-Review Prevenzione del declino cognitivo - mitocondri 2026 https://www.mitochon.it/prevenzione-del-declino-cognitivo/?v=0d149b90e739
85. Mini-Review Coenzima Q10 - Resvreatrolo aterosclerosi - performance muscolare 2026 https://www.mitochon.it/coenzima-q10-novita-di-fine-2025-ed-inizio-2026/?v=0d149b90e739
86. Pipino C, Costabile F, Peláez SM, Tzortzis G, Vulevic J, Costabile A. Oral Postbiotic (VMK223) Supplementation Is Associated with Improved Instrumental Skin Appearance Parameters in Healthy Women Aged 40-55 Years: A Randomized, Double-Blind, Placebo-Controlled Trial. Dermatol Ther (Heidelb). 2026 May 3. doi: 10.1007/s13555-026-01754-6.
87. Yoon Y, Park R, Shim J, Park J, Hwang J, Kim J, Lam KHS, Suryadi T, Suhaimi A. Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain. Nutrients. 2026; 18(11):1675. https://doi.org/10.3390/nu18111675
88. Zhang R, Ge M, Hu M, Zhao Y, Chong B, Li W, Yu J, Lu Y, He S, Wang J, Yue J, Chen HN, Xu H, Peng Y, Lei P, Liu Z, Dai L. Magnesium Deficiency Accelerates Gut Aging and Increases Susceptibility to Colitis. Aging Cell. 2026 Mar;25(3):e70446. doi: 10.1111/acel.70446.
89. Li X, Chen L, Weng Y, Shi Y. Magnesium depletion score and risk of skin cancer and mortality: evidence from NHANES 1999-2018 with mediation by PhenoAge. Cancer Treat Res Commun. 2026;47:101182. doi: 10.1016/j.ctarc.2026.101182.
90. Mini-Review studio pilota Mitofast 2024 https://www.mitochon.it/mitofast-nuovi-ed-importanti-risultati-da-uno-studio-clinico-preliminare/
91. Mini-Review Interazioni Bidirezionali Pelle Cervello 2026 https://www.mitochon.it/interazioni-bidirezionali-pelle-cervello-e-oltre/?v=0d149b90e739
autore Andrea Tognelli, Farmacista - Firenze****
